

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5289526

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SANDRA RODRIGUES PEREIRA FAÇA	06/10/2016
VITOR MARCEL FAÇA	06/10/2016
RECEIVING PARTY DATA	
Name:	VERITAS BIOTECNOLOGIA LTDA
Street Address:	SUPERA SCIENCE PARK, AV. DRA. NADIR AGUILAR
Internal Address:	1805 -- PI 2A SALA 05, JD. DR. PAULO GOMES ROMEO
City:	RIBEIRÃO PRETO, SP
State/Country:	BRAZIL
Postal Code:	CEP 14056-680
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16308443
CORRESPONDENCE DATA	
Fax Number:	(480)830-2717
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	480-830-2700
Email:	aho@boothudall.com
Correspondent Name:	RODNEY J. FULLER, BOOTH UDALL FULLER, PLC
Address Line 1:	1255 W. RIO SALADO PARKWAY
Address Line 2:	SUITE 215
Address Line 4:	TEMPE, ARIZONA 85281
ATTORNEY DOCKET NUMBER:	11170.003US
NAME OF SUBMITTER:	RODNEY J. FULLER
SIGNATURE:	/Rodney J. Fuller/
DATE SIGNED:	12/18/2018
Total Attachments: 2	
source=Assignment_VLS#page1.tif	
source=Assignment_VLS#page2.tif	

ASSIGNMENT

This Assignment is made and executed by **Sandra Rodrigues Pereira Faça** and **Vitor Marcel Faça** (hereinafter "Assignors"), to and in favor of **Veritas Biotecnologia LTDA** having a business address of Supera Science Park, Av. Dra. Nadir Aguiar, 1805, Pl 2A Sala 05, Jd. Dr. Paulo Gomes Romeo, CEP 14056-680, Ribeirao Preto, Sao Paulo, Brazil (hereinafter "Assignee").

Whereas each of the Assignors desires to assign his entire right, title and interest in and to the invention described in the provisional patent application States Patent entitled "NOVEL MONOCLONAL ANTIBODIES PREVENT CELL SURFACE PROTEIN SHEDDING AND BLOCK TUMOR GROWTH" Serial No. 62/348,347 filed on June 10, 2016 (hereinafter the "Patent Application") and all patents, patent applications and the like on the invention to Assignee for valuable consideration; and

Whereas Assignee has provided such valuable consideration to each of the Assignors;

Accordingly, each of the Assignors warrants, covenants and agrees as follows:

1. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in and to the invention described in the Patent Application, including the Patent Application itself and all substitute, continuation, continuation-in-part and divisional applications based in whole or in part on the Patent Application, and including all patents resulting therefrom and all reissues and extensions thereof, and including any and all rights of priority resulting from the filing of any such applications within the United States.

2. Each of the Assignors hereby sells, assigns and conveys to Assignee such Assignor's entire right, title and interest in all counterparts to the Patent Application that have been or may be filed outside the United States or under the Patent Cooperation Treaty, whether pursued as a patent, an inventor's certificate, a utility model or the like, including all rights of priority based on the Patent Application, further including all continuation, continuation-in-part and divisional applications based in whole or in part on the non-U.S. counterparts, and still further including all patents, inventor's certificates, utility models, reissues and extensions resulting from any of the non-U.S. counterparts.

3. Each of the Assignors hereby grants to Assignee the sole and exclusive right to prosecute the Patent Application and all related applications as described in Paragraphs 1 and 2 above, as well as any opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings. Each of the Assignors authorizes all governmental bodies having the power to issue patents, inventor's certificates or utility models to issue a patent, inventor's certificate or utility model based on the Patent Application or any related applications as described in Paragraphs 1 and 2 above in the name of Assignee.

4. Each of the Assignors agrees upon request and without further consideration, but at Assignee's expense: (a) to assist Assignee in prosecuting the Patent Application and all related

ASSIGNMENT

Docket No. 11170.002

Title: "Novel Monoclonal Antibodies Prevent Cell Surface Protein Shedding and Block Tumor Growth"

U.S. Application No. 62/348,347

applications as described in Paragraphs 1 and 2 above, as well as opposition proceedings, reissue applications, reexaminations, and nullity or invalidity proceedings; (b) to provide Assignee with information concerning the Patent Application and the related applications described in Paragraphs 1 and 2 above to enable Assignee to obtain, secure and protect all of the rights, title and interest sold, assigned, conveyed and granted under this Assignment (the "Assigned Assets"); (c) to sign papers, take oaths and testify in legal proceedings to enable Assignee to obtain, secure and protect the Assigned Assets; and (d) to perform all acts reasonably necessary to enable Assignee to obtain, secure and protect the Assigned Assets, including assistance in any proceedings pertaining to the Patent Application and the related applications described in Paragraphs 1 and 2 above or to their enforcement.

5. Each of the Assignors warrants and covenants that such Assignor has the full right to sell, assign and convey the Assigned Assets, that all of the Assigned Assets are free and clear of all mortgages, liens, security interests, charges, claims, royalty obligations and encumbrances of any nature whatsoever and that the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

6. Assignee may assign the Assigned Assets in whole or in part. All references herein to Assignee include any successors or assigns of Assignee.

7. Each of the Assignors acknowledges that Assignee has paid valuable consideration for the Assigned Assets.

June 10, 2016
Date

Sandra Rodrigues Pereira Faça
Sandra Rodrigues Pereira Faça

June 10, 2016
Date

Vitor Marcel Faça
Vitor Marcel Faça